A study sample of 1,704 met inclusion criteria. There were 929 cases in the pre-residency time period (January - September 2013) and 775 cases in the post-residency implementation time period (September 2015 - June 2016). Of the initial cohort, 83 cases (2.2%) were excluded for missing data (Fig. 1).
Patient characteristics including gender, age distribution, triage vital signs and shock index were similar across both time periods (Table 1). In both cohorts, there was a slight male predominance (52.9% and 53.9%) and the majority of patient presented between the ages of 16 to 44 years (55.4% and 57.6%) with an equal proportion of shock index greater than 0.9 (29.0% and 27.7%).
Table 1
Patient presenting characteristics, triage vital signs and shock index by time period (January - September 2013 and September 2015 - June 2016).
| Pre-Residency (N = 929) | Post-Residency Implementation (N = 775) |
Sex (%) | | |
Male | 491 (52.9) | 418 (53.9) |
Female | 438 (47.2) | 357 (46.1) |
Age (%) | | |
Overall Median (IQR) | 41 (29, 59) | 40 (28, 60) |
16–44 | 515 (55.4) | 446 ( 57.6) |
45–65 | 255 (27.5) | 182 (23.5) |
>=65 | 159 (17.1) | 147 (19.0) |
Vital Signs, median (IQR) | | |
Heart Rate | 98 (83, 115) | 96 (81, 112) |
Respiratory Rate | 20 (20, 22) | 20 (18, 20) |
Systolic blood pressure | 123 (107, 141) | 119 (106, 135) |
Shock Index (%) | | |
</= 0.9 | 466 (50.2) | 388 (50.1) |
>0.9 | 269 (29.0) | 215 (27.7) |
Missing | 194 (20.0) | 172 (22.2) |
Prevalence of the top six systems causing pathology in medical patients was not different between time periods (Fig. 2) and included in decreasing prevalence: gastrointestinal (26.3% vs. 25.4%, p = 0.69), infectious disease (13.6% vs. 15.6%, p = 0.23), neurologic (12.2% vs. 10.3%, p = 0.23), pulmonary (7.6% vs. 8.3%, p = 0.64), cardiovascular (8.6% vs. 7.0%, p = 0.21), urologic or renal (6.0% vs. 8.3%, p = 0.07). These six categories encompassed 75% of the total patient cohort.
Differences in EC management observed across the time periods includes increased use of antibiotics (37.2% vs. 42.2%, p = 0.04) and decreased use of vasopressors (1.9% vs. 0.5%, p = 0.01). A decrease in percent patients receiving IV crystalloid fluid resuscitation was noted (55.5% vs. 47.6%, p = 0.001). However, mean amount of crystalloid fluids received when administered increased across time periods (2,057 ml vs. 2,526 ml, ttest = 0.0001, Table 3).
Table 2
All-cause, emergency center, and inpatient mortality stratified by time period. *Incidence of inpatient mortality calculated from amongst those admitted.
All-Cause Mortality | Pre-Residency (N = 929) | Post-Residency Implementation (N = 775) | Chi2 |
Overall | 170 (19.9) | 97 (14.0) | 0.002 |
Gastrointestinal | 29 (12.8) | 18 (9.9) | 0.4 |
Infectious Disease | 37 (30.0) | 23 (22.1) | 0.2 |
Neurologic | 24 (24.0) | 12 (12.1) | 0.3 |
Cardiovascular | 18 (25.4) | 9 (18.4) | 0.4 |
Cancer | 23 (32.4) | 17 (42.5) | 0.3 |
Pulmonary | 14 (22.6) | 7 (13.2) | 0.2 |
EC Mortality | | | |
Overall | 86 (10.0) | 10 (1.4) | < 0.0001 |
Gastrointestinal | 14 (6.2) | 1 (0.6) | 0.003 |
Infectious Disease | 19 (15.5) | 5 (4.8) | 0.009 |
Neurologic | 15 (14.9) | 0 (0) | 0.001 |
Cardiovascular | 12 (16.9) | 1 (2.0) | 0.009 |
Cancer | 5 (8.1) | 1 (1.9) | 0.1 |
Pulmonary | 5 (6.9) | 2 (5.0) | 0.7 |
Inpatient Mortality* | N = 522 | N = 539 | |
Overall | 84 (16.1) | 87 (16.1) | 1.0 |
Gastrointestinal | 15 (10.9) | 17 (12.0) | 0.8 |
Infectious Disease | 18 (22.5) | 18 (24.3) | 0.8 |
Neurologic | 9 (15.3) | 12 (21.1) | 0.4 |
Pulmonary | 9 (36.0) | 6 (16.7) | 0.1 |
Cardiovascular | 6 (14.6) | 8 (18.2) | 0.7 |
Urologic or Renal | 3 (9.1) | 5 (12.5) | 0.6 |
Table 3
EC interventions stratified by time period and top six diagnoses.
EC Intervention | Pre-Residency | Post-Residency | Chi2 |
Overall | N = 937 | N = 780 | |
IV Crystalloid infusion | 516 (55.5) | 369 (47.6) | 0.001 |
IV Fluid amount (ml) | 2057 | 2526 | Ttest = 0.0001 |
Blood products transfused | 88 (16.1) | 58 (14.8) | 0.6 |
Vasopressors | 18 (1.9) | 4 (0.5) | 0.01 |
Intubation | 29 (3.1) | 13 (1.7) | 0.06 |
Antibiotics | 346 (37.2) | 327 (42.2) | 0.04 |
O2 Therapy | 169 (18.2) | 113 (14.6) | 0.046 |
Gastro | N = 244 | N = 197 | |
IV Crystalloid infusion | 169 (69.3) | 125 (63.5) | 0.2 |
IV Fluid amount (ml) | 2784.5 | 3266.8 | Ttest = 0.04 |
Blood products transfused | 20 (8.2) | 12 (6.1) | 0.4 |
Vasopressors | 4 (1.6) | 1 (0.5) | 0.3 |
Intubation | 3 (1.2) | 2 (1.0) | 0.8 |
Antibiotics | 100 (40.9) | 100 (50.7) | 0.04 |
O2 Therapy | 20 (8.2) | 12 (6.1) | 0.4 |
ID | N = 126 | N = 121 | |
IV Crystalloid infusion | 79 (62.7) | 62 (51.2) | 0.07 |
IV Fluid amount (ml) | 2033.8 | 2250 | Ttest = 0.5 |
Blood products transfused | 12 (9.5) | 8 (6.6) | 0.4 |
Vasopressors | 3 (2.4) | 0 (0) | 0.09 |
Intubation | 4 (3.2) | 5 (4.1) | 0.7 |
Antibiotics | 75 (59.5) | 74 (61.2) | 0.8 |
O2 Therapy | 35 (27.8) | 16 (13.2) | 0.005 |
Neuro | N = 113 | N = 80 | |
IV Crystalloid infusion | 62 (54.9) | 37 (46.3) | 0.4 |
IV Fluid Amount (ml) | 1416 | 1595 | Ttest = 0.5 |
Blood products transfused | 3 (2.7) | 0 (0) | 0.2 |
Vasopressors | 1 (0.9) | 1 (1.25) | 0.8 |
Intubation | 13 (11.5) | 2 (2.5) | 0.02 |
Antibiotics | 35 (31.0) | 26 (32.5) | 0.8 |
O2 Therapy | 29 (25.7) | 13 (16.3) | 0.1 |
Pulmonary | N = 71 | N = 64 | |
IV Crystalloid infusion | 29 (40.9) | 27 (42.2) | 0.9 |
IV Fluid Amount (ml) | 1574 | 1761 | Ttest = 0.5 |
Blood products transfused | 1 (1.4) | 2 (3.1) | 0.5 |
Vasopressors | 0 (0) | 0 (0) | |
Intubation | 2 (2.8) | 1 (1.6) | 0.6 |
Antibiotics | 24 (33.8) | 30 (46.9) | 0.1 |
O2 Therapy | 27 (38.0) | 28 (43.8) | 0.5 |
Cardiovascular | N = 80 | N = 54 | |
IV Crystalloid infusion | 32 (40.0) | 10 (18.5) | 0.009 |
IV Fluid Amount | 1629 | 2700 | Ttest = 0.2 |
Blood products transfused | 5 (6.2) | 4 (7.4) | 0.79 |
Vasopressors | 6 (0.4) | 2 (3.7) | 0.4 |
Intubation | 2 (2.5) | 1 (1.9) | 0.8 |
Antibiotics | 18 (22.5) | 9 (16.7) | 0.4 |
O2 Therapy | 30 (37.5) | 19 (35.2) | 0.8 |
Urologic or Renal | N = 56 | N = 64 | |
IV Crystalloid infusion | 18 (32.1) | 15 (23.4) | 0.29 |
IV Fluid Amount | 1233 | 1844 | Ttest = 0.17 |
Blood products transfused | 4 (7.1) | 2 (3.1) | 0.31 |
Vasopressors | 2 (3.6) | 0 (0) | 0.13 |
Intubation | 1 (1.8) | 0 (0) | 0.28 |
Antibiotics | 11 (19.6) | 18 (28.1) | 0.28 |
O2 Therapy | 5 (8.9) | 9 (14.1) | 0.38 |
Overall facilities based all-cause patient mortality decreased between time periods (19.7% vs. 14.0%, p = 0.002). There was no statistical difference in inpatient mortality. ED specific mortality fell from 10.0–1.4% (p < 0.0001) with statistically decreased ED mortality for patients diagnosed with gastrointestinal, infectious, neurologic and cardiovascular disease (Table 2).
When ED interventions were analyzed for each of the top six diagnosis categories by time period, trends in increasing frequency of antibiotic administration were noted for cases with infectious diseases, neurologic pathology and cancer. However, statistically significant increases were seen only for gastrointestinal pathology (40.9% vs. 50.7%, p = 0.04). A decrease in vasopressor use was seen for gastrointestinal pathology, infectious disease, cardiovascular disease, and cancer, although none were statistically significant. Although only cardiovascular reached statistical significance, a trend toward decreasing frequency of IV fluid administration was noted across the top five diagnoses, increasing only in the sixth diagnosis of pulmonary pathology. The mean amount administered increased across all six diagnoses, although only gastrointestinal pathology reached statistical significance.